화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Korean Chemical Engineering Research, Vol.55, No.2, 180-189, April, 2017
DOI10.9713/kcer.2017.55.2.180  Export Citation
PVM 및 FBRM 기반 인라인 모니터링을 통한 indomethacin-saccharin 공결정의 생성 메커니즘이해
Understanding the Mechanism of Indomethacin-Saccharin Co-crystal Formation Using In-line Monitoring System based on PVM and FBRM
김바울, 조민용1, 최광진†
  • 순천향대학교 의료과학대학 의약공학과, 31538 충청남도 아산시 신창면 순천향로 22
  • 1순천향대학교 의료과학대학 의료과학과, 31538 충청남도 아산시 신창면 순천향로 22
Paul Kim, Min-Yong Cho1, and Guang J. Choi†
  • Department of Pharmaceutical Engineering, Soon Chun Hyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si, Chungnam, 31538, Korea
  • 1Department of Medical Science, Soon Chun Hyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si, Chungnam, 31538, Korea
E-mail:
초록
난용성 약물의 용해도를 증가시키고 안정성을 향상하기 위한 제약 공결정은, 미국 FDA가 지난 2016년 8월에 공결정을 solvate의 특별한 경우라고 정의를 수정하면서, 개량신약의 개발에 더욱 박차를 가할 것으로 추측된다. 본 연구에서는 모델 조합으로 잘 알려진 indomethacin-saccharin 공결정을 반용매 방법으로 제조할 때, 인라인 모니터링 기법을 적용하여, 반용매의 주입속도에 따른 indomethacin 준 안정상의 일시적인 생성 및 indomethacin-saccharin 공결정의 생성을 관찰하고 메커니즘을 제안하고자 하였다. 그간 인라인 모니터링을 위해서 매우 다양한 분석도구가 연구되어 왔는데, 본 연구에서는 PVM (particle vision measurement)와 FBRM (focused beam reflectance measurement)를 조합하여 공결정화 공정에서의 변화를 실시간으로 측정하였다. 공결정화 결과물의 오프라인 분석은 PXRD (powder x-ray diffraction)와 DSC (Differential scanning calorimeter)를 이용하여 수행하였다. 반용매의 주입 속도에 따라서 공결정이 생성되는 경로에 분명한 차이가 있음을 관찰하였으며, 이러한 상관 관계의 이해를 통해서 제약학적 특성이 더욱 일정하고 품질이 보증된 indomethacin-saccharin Co-crystal을 얻는 조건을 확립하였다. 본 연구결과, PVM과 FBRM을 조합한 인라인 모니터링은 제약 공결정 제조공정에서 활용성이 매우 높은 기술이라고 할 수 있다.
Pharmaceutical co-crystals primarily to improve the solubility as well as stability of insoluble drug are to be investigated more intensively for IMDs as US FDA has reclassified co-crystal as a special case of solvates in August this year. In this study, we proposed a mechanism of indomethacin-saccharin co-crystal formation and the creation of transient indomethacin meta-stable form using in-line monitoring tools with the addition rate of anti-solvent as a critical process parameter. Among various instruments, we combined PVM (particle vision measurement) and FBRM (focused beam reflectance measurement) for the in-line monitoring of anti-solvent co-crystallization process. The off-line characterization of resulting powders was carried out employing the PXRD (powder x-ray diffraction) and DSC (differential scanning calorimeter). It was observed that the pathway to the final IMC-SAC co-crystal was significantly dependent upon the anti-solvent addition rate. The process conditions to obtain high quality co-crystal powder effectively were established. Consequently, we concluded that in-line monitoring combing the PVM and FBRM should be useful for the in-line monitoring of pharmaceutical co-crystallization processes.
Keywords:Indomethacin (IMC);Saccharin (SAC) Co-crystallization;Anti-solvent;In-line monitoring;FBRM;PVM
  1. Chang JW, Yang DR, Korean Ind. Chem. News, 10(5), 25 (2007)
  2. Sarma B, Chen J, Hsi HY, Myerson AS, Korean J. Chem. Eng., 28(2), 315 (2011)
  3. Liu X, Sun D, Wang F, Wu YJ, Chen Y, Wang L, J. Pharm. Sci., 100(6), 3 (2011)
  4. Lee MJ, Wang IC, Kim MJ, Kim P, Song KH, Chun NH, Park HG, Choi GJ, Korean J. Chem. Eng., 32(9), 1910 (2015)
  5. Genck W, Make The Most of Antisolvent Crystallization, Chemical Processing, Article, Nov 08, 2010.
  6. http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=713.
  7. Surwase SA, Boetker JP, Saville D, Boyd BJ, Gordon KC, Peltonen L, Strachan CJ, Mol. Pharmaceutics, 10, 4472 (2013)
  8. Khomane KS, More PK, Raghavendra G, Bansal AK, Mol. Pharmaceutics, 10, 631 (2013)
  9. Carpentier L, Decressain R, Desprez S, Descamps M, J. Phys. Chem. B, 110, 457 (2005)
  10. Csermely P, Korcsmaros T, Kiss HJ, London G, Nussinov R, Pharmacol. Ther., 138(3), 333 (2013)
  11. Stegemann S, Leveiller F, Franchi D, De Jong H, Linden H, Eur. J. Pharm. Sci., 31(5), 249 (2007)
  12. Di L, Fish PV, Mano T, Bridging Solubility Between Drug Discovery and Development., Drug Discovery Today, 486-495(2012).
  13. Turner JR, Drug Discovery. In New Drug Development; Springer: New York, pp 21-34(2010).
  14. Li P, Zhao L, Int. J. Pharm., 341, 1 (2007)
  15. Baird JA, J. Pharm. Sci., Baird JA, Van Eerdenbrugh B, Taylor LS, A classification System to Assess the Crystallization Tendency of Organic Molecules From Undercooled Melts,” J. Pharm. Sci., 2010, 99 (9), 3787-3806(2010)., 3787 (2010)
  16. Engers D, Teng J, Jimenez-Novoa J, Gent P, Hossack S, Campbell C, Thomson J, Ivanisevic I, Templeton A, Byrn S, Newman A, J. Pharm. Sci., 99(9), 3901 (2010)
  17. Neervannan S, Expert Opin. Drug Metab. Toxicol., 2(5), 715 (2006)
  18. Hancock BC, Zografi G, J. Pharm. Sci., 86(1), 1 (1997)
  19. Laitinen R, Lobmann K, Strachan CJ, Grohganz H, Rades T, Int. J. Pharm., 453, 65 (2013)
  20. Bhugra C, Pikal MJ, J. Pharm. Sci., 97(4), 1329 (2008)
  21. Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, Yliruusi J, Eur. J. Pharm. Biopharm., 71(1), 71 (2009)
  22. Wu T, Sun Y, Li N, de Villiers MM, Yu L, Langmuir, 23(9), 5148 (2007)
  23. Alonzo D, Zhang G, Zhou D, Gao Y, Taylor L, Pharm. Res., 27, 608 (2010)
  24. Greco K, Bogner R, Mol. Pharmaceutics, 7(5), 1406 (2010)
  25. Andronis V, Yoshioka M, Zografi G, J. Pharm. Sci., 86(3), 346 (1997)
  26. Andronis V, Zografi G, J. Non-Cryst. Solids, 271, 236 (2000)
  27. Hancock BC, Shamblin SL, Zografi G, Pharm. Res., 12(6), 799 (1995)
  28. Borka L, Acta Pharm. Suec., 11, 295 (1974)
  29. Lin SY, J. Pharm. Sci., 81(6), 572 (1992)
  30. Takiyama H, Minamisono T, Osada Y, Matsuoka M, Chem. Eng. Res. Des., 88(9A), 1242 (2010)
  31. Wang X, de Armas HN, Blaton N, Michoel A, den Mooter GV, Int. J. Pharm., 345, 95 (2007)
  32. Chen XM, Morris KR, Griesser UJ, Byrn SR, Stowell JG, J. Am. Chem. Soc., 124(50), 15012 (2002)
  33. Qi S, Craig DQM, Mol. Pharmaceutics, 9, 1087 (2012)
  34. Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-Reshteh-dar S, Soleymania A, Iran. J. Pharm. Res., 10(1), 25 (2011)
  35. Alsaidan SM, Alsughayer AA, Eshra AG, Drug Dev. Ind. Pharm., 24, 389 (1998)
  36. Chun NH, Wang IC, Lee MJ, Jung YT, Lee S, Kim WS, Choi GJ, Eur. J. Pharm. Biopharm., 85(3), 854 (2013)
  37. Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ, Int. J. Pharm., 450(1-2), 311 (2013)
  38. De Beer TR, Baeyens WR, Ouyang J, Vervaet C, Remon JP, Analyst, 131(10), 1137 (2006)
  39. Kim JY, Kwon K, Yakhak Hoeji, 57(6), 432 (2013)
  40. http://www.dailypharm.com/News/184408.
  41. http://www.yonhapnews.co.kr/bulletin/2016/07/27/0200000000AKR20160727096700017.HTML?input=1195m.
  42. Kelly AL, Gough T, Dhumal RS, Halsey SA, Paradkar A, Int. J. Pharm., 426(1-2), 15 (2012)
  43. U. S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070305.pdf).
  44. Su M, Wang L, Sun H, Wang JK, Frontiers of Chemical Engineering in China, 3(3), 282 (2009)
  45. Liu X, Sun D, Wang F, Wu YJ, Chen Y, J. Pharm. Sci., 100(6) (2011)
  46. Leyssens T, Org. Process Res., 413 (2011)
  47. Jia CY, Yin QX, Zhang MJ, Wang JK, Shen ZH, “Polymorphic Transformation of Pravastatin Sodium Monitored Using Combined Online FBRM and PVM,” Organic Process Research & Development, 12(6), (2008).